{
  "trial_id": "NCT01445769",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Diagnosis of Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis",
      "label": "met",
      "evidence": "bone marrow biopsy"
    },
    {
      "criterion": "Must score at least 2 points on the Dynamic International Prognostic Scoring System (DIPSS) scale for prognostic risk factors.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Peripheral blast count < 5% at both Screening and Baseline hematology assessments.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Must discontinue all drugs used to treat underlying myelofibrosis (MF) disease no later than Day -1 (the day prior to starting ruxolitinib).",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Must have hemoglobin value \u2265 6.5 g/dL and be willing to receive blood transfusions.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Platelet count \u2265 100*10^9/L.",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Must have a palpable spleen.",
      "label": "met",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Invasive malignancies over the previous 5 years (except treated early stage carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix, and completely resected papillary thyroid and follicular thyroid cancers).",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Splenic irradiation within 6 months prior to receiving the first dose of study medication.",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "Patient has no other underlying disease and is not on any medications.",
  "_meta": {
    "topic_id": "32",
    "trial_id": "NCT01445769",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}